Editas Medicine, Inc. (EDIT): Price and Financial Metrics
EDIT Price/Volume Stats
| Current price | $5.55 | 52-week high | $11.91 |
| Prev. close | $5.61 | 52-week low | $5.51 |
| Day low | $5.51 | Volume | 1,715,500 |
| Day high | $5.68 | Avg. volume | 1,822,969 |
| 50-day MA | $7.79 | Dividend yield | N/A |
| 200-day MA | $8.41 | Market Cap | 454.07M |
EDIT Stock Price Chart Interactive Chart >
Editas Medicine, Inc. (EDIT) Company Bio
Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest EDIT News From Around the Web
Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Editas Just Caught a Break Thanks to Vertex PharmaceuticalsEditas isn't out of the woods yet, but it's better off than before. |
Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making... |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent Newsbluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news. |
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy. |
EDIT Price Returns
| 1-mo | -29.92% |
| 3-mo | -31.40% |
| 6-mo | -11.76% |
| 1-year | -27.45% |
| 3-year | -83.90% |
| 5-year | -78.49% |
| YTD | -45.21% |
| 2023 | 14.21% |
| 2022 | -66.59% |
| 2021 | -62.13% |
| 2020 | 136.78% |
| 2019 | 30.15% |
Continue Researching EDIT
Want to do more research on Editas Medicine Inc's stock and its price? Try the links below:Editas Medicine Inc (EDIT) Stock Price | Nasdaq
Editas Medicine Inc (EDIT) Stock Quote, History and News - Yahoo Finance
Editas Medicine Inc (EDIT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...